90 related articles for article (PubMed ID: 7803769)
1. [Somatostatin receptor scintigraphy in endocrine orbitopathy].
Diaz M; Kahaly G; Mühlbach A; Bockisch A; Beyer J; Hahn K
Rofo; 1994 Dec; 161(6):484-8. PubMed ID: 7803769
[TBL] [Abstract][Full Text] [Related]
2. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
[TBL] [Abstract][Full Text] [Related]
3. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
[TBL] [Abstract][Full Text] [Related]
5. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
6. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G
J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327
[TBL] [Abstract][Full Text] [Related]
7. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin-receptor scintigraphy in Graves' orbitopathy.
Postema PT; Kwekkeboom DJ; van Hagen PM; Krenning EP
Eur J Nucl Med; 1996 Jun; 23(6):615-7. PubMed ID: 8662098
[No Abstract] [Full Text] [Related]
10. Somatostatin receptors in the orbits.
Durak I; Durak H; Ergin M; Yürekli Y; Kaynak S
Clin Nucl Med; 1995 Mar; 20(3):237-42. PubMed ID: 7750218
[TBL] [Abstract][Full Text] [Related]
11. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
[TBL] [Abstract][Full Text] [Related]
12. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy.
Kahaly G; Diaz M; Just M; Beyer J; Lieb W
Thyroid; 1995 Apr; 5(2):107-11. PubMed ID: 7647569
[TBL] [Abstract][Full Text] [Related]
13. Indium-111-pentetreotide in Graves' disease.
Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A
J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.
Nocaudie M; Bailliez A; Itti E; Bauters C; Wemeau JL; Marchandise X
Eur J Nucl Med; 1999 May; 26(5):511-7. PubMed ID: 10382096
[TBL] [Abstract][Full Text] [Related]
15. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease.
Burggasser G; Hurtl I; Hauff W; Lukas J; Greifeneder M; Heydari B; Thaler A; Wedrich A; Virgolini I
J Nucl Med; 2003 Oct; 44(10):1547-55. PubMed ID: 14530465
[TBL] [Abstract][Full Text] [Related]
16. [[111In]-DTPA-D-phenylalanine octreotide SPECT for the scintigraphic imaging of enhanced somatostatin-receptor density in endocrine ophthalmopathy].
Cordes M; Hosten N; Gräf KJ; Wenzel KW; Venz S; Keske U; Eichstädt H; Felix R
Rofo; 1994 Jan; 160(1):11-5. PubMed ID: 8305685
[TBL] [Abstract][Full Text] [Related]
17. The role of octreoscan in thyroid eye disease.
Krassas GE; Kahaly GJ
Eur J Endocrinol; 1999 May; 140(5):373-5. PubMed ID: 10229898
[TBL] [Abstract][Full Text] [Related]
18. [Clinical application of orbital scintigraphy with 99Tc(m)-octreotide in patients with thyroid associated ophthalmopathy].
Duan L; Li XF; Lu KY; Zhang CG; Hu G; Liu JZ; Li SJ
Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1068-72. PubMed ID: 17415962
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity.
Förster GJ; Krummenauer F; Nickel O; Kahaly GJ
Cancer Biother Radiopharm; 2000 Oct; 15(5):517-25. PubMed ID: 11155823
[TBL] [Abstract][Full Text] [Related]
20. [Octreotide scintigraphy in thyroid orbitopathy].
Aguirre-Balsalobre F; Mengual-Verdú E; Muñoz-Acosta JM; Martínez-Caballero A; Caballero-Carpena O; Hueso-Abacens JR
Arch Soc Esp Oftalmol; 2007 Mar; 82(3):133-9. PubMed ID: 17357889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
